The ROS-1 Market has become a vital component of precision oncology, fueled by remarkable progress in understanding ROS1 gene rearrangements and the creation of highly targeted therapeutic interventions. These specialized treatments primarily address ROS1-positive non-small cell lung cancer (NSCLC), where ROS1 rearrangements appear in approximately 1-2% of patients, creating distinct...
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek